# OptiTROP-Lung04: what clinicians are saying

> 125 statements from 38 sources (1 podcast, 6 videos, 29 posts, 1 paper, 1 registry record), 52 of them from 16 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026.

## Report

- Trial: A Randomized, Open-Label, Multicenter Phase 3 Study to Evaluate SKB264 Monotherapy Versus Pemetrexed in Combination With Platinum in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutation Who Have Failed to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Therapy
- NCT ID: NCT05870319
- Registry: https://clinicaltrials.gov/study/NCT05870319
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs tested: sacituzumab tirumotecan (SKB264)
- Indication: EGFR-TKI-resistant, EGFR-mutated advanced NSCLC
- Version: v1.0.0, edition 1
- Accepted: 2026-11-20 UTC
- Last checked: 2026-11-20 UTC
- Release hash: 9d960d780150a19405aa25d85f2ca1c6ebb6322b4aaea7c51101c751699811a5

## Counts

- Commentary sources screened: 71
- Sources cited by verified statements: 38
- Verified statements: 125
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 52
- Findings: 11
- Named people in screened sources (unnamed speakers and accounts not counted): 28
- Speakers cited: 28
- Cited speakers with a verified identity: 24
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 16
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 16
- By role and specialty (the abstract's specialty counts):
  - 15 physician, Medical oncology
  - 1 physician, specialty not confirmed
- Organisational or shared accounts (not counted as people): 2

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

The clinicians cited read OptiTROP-Lung04 as supporting an active option that could move platinum later in treatment, but differ on readiness to use sac-TMT. One medical oncologist supports treatment change where it is available; another anticipates future rather than immediate change. A speaker would move toward sac-TMT only with access and global replication. Clinicians still seek CNS data, while final survival estimates are described through commentary rather than a separate final-results publication.

## Question clinicians left open

Where sacituzumab tirumotecan is available outside China, is global confirmation of OptiTROP-Lung04 needed before using it to defer platinum chemotherapy after EGFR-TKI progression in advanced EGFR-mutant NSCLC?

From findings F1 (16 statements from 9 speakers in 11 sources) and F2 (13 statements from 8 speakers in 10 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Uptake: what speakers say
  - 16 statements from 9 speakers in 11 sources, 4 of them podcasts or videos.
  - 6 of the report's 16 cited clinicians.
- F2. China-only evidence: where speakers split on requiring global confirmation
  - 13 statements from 8 speakers in 10 sources, 2 of them podcasts or videos.
  - 6 of the 8 named speakers in this finding take a side on this question: 5 on one side, 1 on the other.
  - 5 of the report's 16 cited clinicians.
- F3. Grade ≥3: what speakers say
  - 19 statements from 10 speakers in 14 sources, 4 of them podcasts or videos.
  - 5 of the report's 16 cited clinicians.
- F4. CNS activity: why most clinicians seek more evidence on brain metastases
  - 7 statements from 5 speakers in 6 sources, 1 of them a podcast or video.
  - 4 of the 5 named speakers in this finding hold this view, each a confirmed clinician.
  - 5 of the report's 16 cited clinicians.
- F5. OS benefit: most speakers highlight its size; a clinician notes a nominal p value
  - 25 statements from 14 speakers in 18 sources, 2 of them podcasts or videos.
  - 12 of the 14 named speakers in this finding hold this view; 1 of the 14 holds its caveat, “a clinician notes a nominal p value”.
  - 9 of the report's 16 cited clinicians.
- F6. Post-EGFR-TKI: most speakers weigh options but a clinician cannot yet rank them
  - 20 statements from 7 speakers in 12 sources, 4 of them podcasts or videos.
  - 5 of the 7 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician cannot yet rank them”.
  - 4 of the report's 16 cited clinicians.
- F7. Post-EGFR-TKI choices: why speakers want testing and biomarkers to guide therapy
  - 11 statements from 3 speakers in 4 sources, 1 of them a podcast or video.
  - 3 of the 3 named speakers in this finding hold this view.
  - 2 of the report's 16 cited clinicians.
- F8. TROP2 ADCs: where speakers split on class-wide versus drug-specific implications
  - 9 statements from 7 speakers in 7 sources, 3 of them podcasts or videos.
  - 5 of the 7 named speakers in this finding take a side on this question: 3 on one side, 2 on the other.
  - 3 of the report's 16 cited clinicians.

### Beyond the trial population

- F9. ADC R&D: what speakers say
  - 8 statements from 6 speakers in 7 sources, 3 of them podcasts or videos.
  - 3 of the report's 16 cited clinicians.
- F10. Prior ADC work: most speakers note activity signals; most see care changing
  - 9 statements from 3 speakers in 6 sources, 2 of them podcasts or videos.
  - 2 of the 3 named speakers in this finding hold this view; 2 of the 3 hold its caveat, “most see care changing”.
  - 1 of the report's 16 cited clinicians.
- F_C116_cross_population_context. From EGFR-mutant to PD-L1-negative NSCLC: how a speaker sees an ADC shift
  - 1 statement from 1 speaker in 1 source.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.

3 of the 11 findings and 12 of the 125 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 16 | 15 | 11 | 9 | 3 |
| F2 | 13 | 10 | 10 | 8 | 4 |
| F3 | 19 | 17 | 14 | 10 | 5 |
| F4 | 7 | 7 | 6 | 5 | 3 |
| F5 | 25 | 23 | 18 | 14 | 3 |
| F6 | 20 | 14 | 12 | 7 | 5 |
| F7 | 11 | 7 | 4 | 3 | 4 |
| F8 | 9 | 8 | 7 | 7 | 3 |
| F9 | 8 | 9 | 7 | 6 | 4 |
| F10 | 9 | 6 | 6 | 3 | 4 |
| F_C116_cross_population_context | 1 | 1 | 1 | 1 | 1 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 16 | 0 | 0 | 0 | 0 | 16 | 1 | 7 posts and articles, 4 podcasts and video |
| F2 | 9 | 3 | 0 | 0 | 1 | 16 | 1 | 8 posts and articles, 2 podcasts and video |
| F3 | 8 | 0 | 0 | 3 | 8 | 20 | 2 | 9 posts and articles, 4 podcasts and video, 1 publication |
| F4 | 4 | 3 | 0 | 0 | 0 | 7 | 0 | 5 posts and articles, 1 podcast or video |
| F5 | 11 | 1 | 0 | 1 | 12 | 29 | 3 | 15 posts and articles, 2 podcasts and video, 1 publication |
| F6 | 7 | 2 | 0 | 5 | 6 | 22 | 1 | 7 posts and articles, 4 podcasts and video, 1 publication |
| F7 | 5 | 2 | 1 | 0 | 3 | 12 | 0 | 2 posts and articles, 1 podcast or video, 1 publication |
| F8 | 6 | 0 | 0 | 1 | 2 | 9 | 1 | 4 posts and articles, 3 podcasts and video |
| F9 | 6 | 1 | 0 | 0 | 1 | 10 | 0 | 4 posts and articles, 3 podcasts and video |
| F10 | 5 | 0 | 0 | 0 | 4 | 9 | 0 | 4 posts and articles, 2 podcasts and video |
| F_C116_cross_population_context | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 post or article |

### Trial dimensions

- Primary endpoint: Progression-free survival (PFS): F1 (3 shared claims), F3 (2 shared claims), F4 (1 shared claims), F5 (9 shared claims)
- Secondary endpoints: F1 (1 shared claims), F3 (2 shared claims), F4 (1 shared claims), F5 (16 shared claims)
- Population and setting: F1 (2 shared claims), F3 (1 shared claims), F5 (1 shared claims), F6 (2 shared claims), F7 (4 shared claims), F8 (2 shared claims)
- The comparison: F1 (1 shared claims), F2 (1 shared claims), F3 (1 shared claims), F4 (1 shared claims), F5 (1 shared claims), F6 (19 shared claims), F7 (2 shared claims), F8 (1 shared claims)
- Safety and tolerability: F1 (3 shared claims), F3 (16 shared claims), F5 (1 shared claims), F6 (1 shared claims)
- Design and conduct: F2 (9 shared claims), F3 (1 shared claims), F5 (5 shared claims), F7 (2 shared claims)

## Abbreviations

- ADC: antibody–drug conjugate
- CNS: central nervous system
- EGFR: epidermal growth factor receptor
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- NSCLC: non-small cell lung cancer
- OS: overall survival
- PD-L1: programmed death-ligand 1
- PFS: progression-free survival

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 11 | Titles free |
| Detailed analysis | 13 sections | Paid |
| Verified statements with short source quotes and links | 125 | Paid |
| Who said each statement: the cited speakers | 28 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 16 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 24 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 38 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 16 of the 28 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

14 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression-free survival (PFS) | discussed | 15 | 14 |
| Secondary endpoints | discussed | 19 | 16 |
| Population and setting | discussed | 15 | 7 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 20 | 12 |
| Safety and tolerability | discussed | 18 | 13 |
| Design and conduct | discussed | 16 | 9 |
| Practice-change thresholds and platinum deferral | discussed | 17 | 13 |
| Geographic applicability, regulatory translation and access | discussed | 14 | 11 |
| Intracranial activity and patient-relevant outcomes | discussed | 7 | 6 |
| Resistance work-up and treatment sequencing | discussed | 13 | 6 |
| Biological rationale and ADC differentiation | discussed | 9 | 7 |
| Earlier-study context and uncertain study descriptions | discussed | 11 | 8 |
| Future combinations and earlier-line development | discussed | 9 | 8 |
| Analysis maturity, subsequent therapy and statistical interpretation | discussed | 17 | 11 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 48 statements · 39%** | | | |
| YouTube | 38 | 6 | 8 |
| Podcasts | 10 | 1 | 1 |
| **Posts · 73 statements · 58%** | | | |
| X threads | 34 | 15 | 33 |
| LinkedIn posts | 34 | 11 | 11 |
| Bluesky threads | 5 | 3 | 18 |
| **Primary sources · 4 statements · 3%** (cited for context, not screened) | | | |
| Publications (primary source, cited for context) | 3 | 1 | not screened |
| Registry (primary source, cited for context) | 1 | 1 | not screened |

- Screened window: 2023-07-25 to 2026-11-13
- Cited window: 2025-06-01 to 2026-11-13
- Retrieved: 2026-11-19

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Randomized, Open-Label, Multicenter Phase 3 Study to Evaluate SKB264 Monotherapy Versus Pemetrexed in Combination With Platinum in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutation Who Have Failed to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Therapy
- Also known as: OptiTROP-4
- Registry: NCT05870319 (https://clinicaltrials.gov/study/NCT05870319)
- Study IDs: SKB264-Ⅲ-09
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 376 (actual)
- Start: 2023-06-26 (actual)
- Primary completion: 2024-07-11 (actual)
- Primary endpoint: Progression-free survival (PFS) (From baseline until disease progression, death, or other protocol defined reason,up to approximately 36 months)
- Intervention: SKB264 (drug)
- Intervention: Pemetrexed (drug)
- Intervention: Carboplatin (drug)
- Intervention: Cisplatin (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 1 matching source (1 X thread) could not be read and is not included.
- Not yet captured in this edition: a view on alternative antibody–drug conjugates’ benefit–risk, evidence maturity and geographic applicability after EGFR-TKI failure; a view on alternative ADC efficacy, toxicity, dose modification and supportive-care needs after EGFR-TKI failure.
- 57 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 64 sources about other trials or topics are not included.
- The sources reviewed for this edition are not a representative sample of HCPs. Repeated posts and presentation summaries do not establish independent agreement.
- Public discussion that did not use recognizable trial names or wording may be absent. One potentially relevant X discussion could not be read.
- Several recorded passages cannot be attributed to a named speaker. They remain attached to their discussion or episode and cannot establish additional independent participants.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The linked publication reports final PFS and preplanned interim OS. Final OS estimates in this report come from commentary about the 2026 update, not a separate final-results publication.
- Some sources differ on the comparator, treatment history, endpoint hierarchy, safety measure or study name. Their descriptions remain attributed commentary rather than a single reconciled result.
- No full protocol was available in the sources reviewed, and the regulatory material does not establish an exact label for SKB264. The report therefore does not determine regulatory status or resolve protocol-level questions.
- Earlier or unidentified sac-TMT studies provide contextual material, not evidence for Lung04's own platinum-comparator result.
- Descriptions of alternative-regimen and access discussions are incomplete. SAFFRON is represented here by biomarker-selection comments rather than a full quantitative benefit–risk assessment, and not every speaker's assessment of the other ADCs is available. The report therefore cannot provide an exhaustive account of reasons to choose or withhold each alternative.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-20 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-20 UTC. No changes.

## Offer

- Size: Focused · 125 verified statements · 52 from 16 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (24 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/optitrop-lung04-nct05870319
- Agents: POST https://www.erudio.com/api/orders with {"report": "optitrop-lung04-nct05870319", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=optitrop-lung04-nct05870319

## Cite

Erudio Health. OptiTROP-Lung04 (NCT05870319): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 20, 2026. https://www.erudio.com/reports/optitrop-lung04-nct05870319

## Questions

### How much does the OptiTROP-Lung04 report cost?

One edition costs $750 (Focused · 125 verified statements · 52 from 16 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the OptiTROP-Lung04 report cover?

125 statements from 38 sources (1 podcast, 6 videos, 29 posts, 1 paper, 1 registry record), 52 of them from 16 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the OptiTROP-Lung04 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "optitrop-lung04-nct05870319" }) previews it and create_order({ "report": "optitrop-lung04-nct05870319", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the OptiTROP-Lung04 report?

Edition 1 (version 1.0.0), accepted Nov 20, 2026 UTC; last checked for new commentary Nov 20, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/optitrop-lung04-nct05870319.json
- Markdown: https://www.erudio.com/reports/optitrop-lung04-nct05870319.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/optitrop-lung04-nct05870319/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "optitrop-lung04-nct05870319"}`
